Literature DB >> 25176122

Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey.

H Shen1, G Shahzad, M Jawairia, R M Bostick, P Mustacchia.   

Abstract

BACKGROUND: Many basic mechanistic studies found that aspirin inhibited multiple pathways involved in non-alcoholic fatty liver disease (NAFLD) development. AIM: To investigate an association between aspirin use and NAFLD prevalence in the general US population.
METHODS: We conducted a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey (NHANES III). We included 11 416 adults aged 20-74 years who underwent ultrasonography; of those, 2889 were identified as having NAFLD and 8527 as controls. Aspirin use during the month prior to interview was categorised as never use (0 times), occasional use (1-14 times) and regular use (≥15 times).
RESULTS: In the multivariate unconditional logistic regression analysis, regular relative to no aspirin use was inversely associated with prevalent NAFLD [odds ratio (OR) = 0.62, 95% confidence interval (CI) 0.51-0.74; P for trend = 0.04], a finding that was primarily limited to men (OR = 0.32, 95% CI 0.23-0.45; P for interaction < 0.01) and those who were older (>60 years) (OR = 0.21, 95% CI 0.14-0.30; P for interaction < 0.01).
CONCLUSION: These findings, from the first human study to investigate an association of aspirin use with NAFLD, suggest that regular aspirin use (≥ 15 times per month) may be associated with a lower prevalence of NAFLD, primarily among men and older patients.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25176122     DOI: 10.1111/apt.12944

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  17 in total

1.  Histamine H2-Receptor Antagonist Use Is Associated With Lower Prevalence of Nonalcoholic Fatty Liver Disease: A Population-based Study From the National Health and Nutrition Examination Survey, 2001-2006.

Authors:  Huafeng Shen; Suthat Liangpunsakul
Journal:  J Clin Gastroenterol       Date:  2016-08       Impact factor: 3.062

Review 2.  Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases.

Authors:  Han Ah Lee; Young Chang; Pil Soo Sung; Eileen L Yoon; Hye Won Lee; Jeong-Ju Yoo; Young-Sun Lee; Jihyun An; Do Seon Song; Young Youn Cho; Seung Up Kim; Yoon Jun Kim
Journal:  Clin Mol Hepatol       Date:  2022-07-01

3.  Association Between Aspirin Use and Risk of Hepatocellular Carcinoma.

Authors:  Tracey G Simon; Yanan Ma; Jonas F Ludvigsson; Dawn Q Chong; Edward L Giovannucci; Charles S Fuchs; Jeffrey A Meyerhardt; Kathleen E Corey; Raymond T Chung; Xuehong Zhang; Andrew T Chan
Journal:  JAMA Oncol       Date:  2018-12-01       Impact factor: 31.777

Review 4.  Platelets as Modulators of Liver Diseases.

Authors:  Ton Lisman; James P Luyendyk
Journal:  Semin Thromb Hemost       Date:  2017-09-12       Impact factor: 4.180

5.  Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.

Authors:  Mohsen Malehmir; Dominik Pfister; Suchira Gallage; Marta Szydlowska; Donato Inverso; Elena Kotsiliti; Valentina Leone; Moritz Peiseler; Bas G J Surewaard; Dominik Rath; Adnan Ali; Monika Julia Wolf; Hannah Drescher; Marc E Healy; Daniel Dauch; Daniela Kroy; Oliver Krenkel; Marlene Kohlhepp; Thomas Engleitner; Alexander Olkus; Tjeerd Sijmonsma; Julia Volz; Carsten Deppermann; David Stegner; Patrick Helbling; César Nombela-Arrieta; Anahita Rafiei; Martina Hinterleitner; Marcel Rall; Florian Baku; Oliver Borst; Caroline L Wilson; Jack Leslie; Tracy O'Connor; Christopher J Weston; Abhishek Chauhan; David H Adams; Lozan Sheriff; Ana Teijeiro; Marco Prinz; Ruzhica Bogeska; Natasha Anstee; Malte N Bongers; Mike Notohamiprodjo; Tobias Geisler; Dominic J Withers; Jerry Ware; Derek A Mann; Hellmut G Augustin; Alexandros Vegiopoulos; Michael D Milsom; Adam J Rose; Patricia F Lalor; Josep M Llovet; Roser Pinyol; Frank Tacke; Roland Rad; Matthias Matter; Nabil Djouder; Paul Kubes; Percy A Knolle; Kristian Unger; Lars Zender; Bernhard Nieswandt; Meinrad Gawaz; Achim Weber; Mathias Heikenwalder
Journal:  Nat Med       Date:  2019-04-01       Impact factor: 53.440

Review 6.  Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.

Authors:  Rosa Lombardi; Simona Onali; Douglas Thorburn; Brian R Davidson; Kurinchi Selvan Gurusamy; Emmanuel Tsochatzis
Journal:  Cochrane Database Syst Rev       Date:  2017-03-30

Review 7.  Avicenna's Canon of Medicine: a review of analgesics and anti-inflammatory substances.

Authors:  Shahla Mahdizadeh; Maryam Khaleghi Ghadiri; Ali Gorji
Journal:  Avicenna J Phytomed       Date:  2015 May-Jun

8.  Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis.

Authors:  Elena Buzzetti; Audrey Linden; Lawrence Mj Best; Angela M Madden; Danielle Roberts; Thomas J G Chase; Suzanne C Freeman; Nicola J Cooper; Alex J Sutton; Dominic Fritche; Elisabeth Jane Milne; Kathy Wright; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-06-11

9.  Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.

Authors:  Oluyemi Komolafe; Elena Buzzetti; Audrey Linden; Lawrence Mj Best; Angela M Madden; Danielle Roberts; Thomas Jg Chase; Dominic Fritche; Suzanne C Freeman; Nicola J Cooper; Alex J Sutton; Elisabeth Jane Milne; Kathy Wright; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-07-19

Review 10.  Platelets: No longer bystanders in liver disease.

Authors:  Abhishek Chauhan; David H Adams; Steve P Watson; Patricia F Lalor
Journal:  Hepatology       Date:  2016-04-07       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.